Beijing Centaurus Biopharma

Centaurus Biopharma is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-unmet-need areas including oncology, metabolic diseases, and inflammatory disorders. Its lead candidate, CT-707, is a multi-kinase inhibitor targeting Focal Adhesion Kinase (FAK) currently in mid-to-late-stage clinical trials for non-small cell lung cancer. Centaurus leverages an integrated R&D platform to advance a diverse pipeline of targeted therapies, including BTK inhibitors and GPR119 agonists. The company was founded by industry veterans with extensive experience in global drug development and is backed by prominent venture capital firms.